Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

• Status: Active, not recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the improvement in signs of photoaging and subject satisfaction after combination, global facial and/or neck treatment with IncobotulinumA (Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All products will be used on-label FDA-cleared indications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Main Line Center for Laser Surgery
• Collaborator: Merz North America, Inc.
• Treatments: incobotulinumtoxinA

Criteria

Inclusion Criteria:

• Age >21

• No toxin treatment in last 3 months

• No filler treatment in last 3 months

• Glogau facing aging scale >=1

Exclusion Criteria:

• Pregnancy

• Breastfeeding

• Allergy to prior Radiesse, Belotero, Xeomin products

• History of any facial nerve palsy (ie. Bell's Palsy)